GS71 GER Week ended 07 Aug 2026

Weekly Investor Report

GSK plc · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 22.86 EUR
1.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -0.2% below the Trend Line and sits at 71.1% of its 52-week range. The latest completed week returned 1.2%, after a -0.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.

Setup score 53 out of 100
Latest Close 22.86 EUR 7 Aug 2026
1W Return 1.2% latest completed week
4W Return -0.5% short-term follow-through
12W Return 7.2% quarterly tape
Trend Breadth 63.5% 33 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Next-week expectancy is positive at 57.63% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.2% Latest completed week; four-week move -0.5%. Indicator stack 35/53 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 57.63% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 2 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -0.2% below the Trend Line and sits at 71.1% of its 52-week range. The latest completed week returned 1.2%, after a -0.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4112-week average 0.54

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.41Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.5% over four weeks, 7.2% over 12 weeks, and 45.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.2%
4W-0.5%
12W7.2%
26W-8.3%
52W45.6%
Active trend streak0 weeks
Active weeks in one year33
Trend breadth63.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.16Latest activity-pressure read.
Pressure change74.6%Four-week change in activity pressure.
Leadership-0.11Latest relative-leadership reading.
RS change-101.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength81/100Blend of value, momentum, and quality. Underlying universe rank 20; rank 1 is best.
Value39/100Relative valuation strength. Underlying universe rank 62; rank 1 is best.
Quality97/100Profitability and accounting quality. Underlying universe rank 4; rank 1 is best.
Momentum84/100Medium-term price momentum. Underlying universe rank 17; rank 1 is best.
Growth88/100Revenue and earnings growth. Underlying universe rank 13; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
15.7x
Price divided by trailing earnings.
Price / sales
2.8x
Market value relative to trailing revenue.
EV / EBITDA
10.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
72.7%
Gross profit retained from each unit of revenue.
Operating margin
25.7%
Operating profit retained from revenue.
Free-cash-flow margin
14.5%
Free cash flow generated from revenue.
Return on invested capital
18.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
4.1%
Latest one-year revenue growth.
EPS growth
125.8%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
33.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
9/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.4%
Cash dividends relative to market value.
Buyback yield
1.6%
Net share repurchases relative to market value.
Shareholder yield
5.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 2 relevant articles.

0 positive · 2 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-11.2%Distance below the 52-week high.
13-week volatility2.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+4.9%Week of 27 Mar.
Worst week-6.0%Week of 6 Mar.
Latest week+1.2%Week of 7 Aug.

Shape of recent returns

Strong gains2
Modest gains10
Flat weeks0
Modest losses9
Sharp losses5
Recent vol2.2%13-week weekly-return volatility.
Base vol3.9%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.1% / -2.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape52/100

Trend, activity pressure, participation, and risk combine to a 52/100 tape read.

 Indicator analysis35/100

Latest 12-week confirmation: trend 1/12, activity pressure 0/12, relative leadership 11/12.

Activity pressure 0.41; No reversal markers Next-Week ExpectancyPositive 57.63%

Next-week expectancy is positive with a 57.63% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors75/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 24 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 2 relevant articles.

GSK plc (GSK) stock price, news, quote and history Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202622.86 EUR1.2%22.89 EUR18.09 EUR-0.16-0.11169.6KOff
31 Jul 202622.58 EUR0.2%22.85 EUR18.04 EUR-0.331.82279.1KOff
24 Jul 202622.53 EUR-0.3%22.79 EUR17.99 EUR-0.444.23238.9KOff
17 Jul 202622.59 EUR-1.7%22.72 EUR17.93 EUR-0.486.25279.8KOff
10 Jul 202622.98 EUR-1.6%22.65 EUR17.88 EUR-0.647.76121.6KOn
3 Jul 202623.35 EUR1.6%22.56 EUR17.83 EUR-0.717.1129.3KOff
26 Jun 202622.98 EUR3.6%22.46 EUR17.77 EUR-0.8910.7436.1KOff
19 Jun 202622.19 EUR-3.5%22.37 EUR17.71 EUR-1.086.237.7KOff
12 Jun 202623.00 EUR2.6%22.30 EUR17.67 EUR-1.1412.2133.6KOff
5 Jun 202622.41 EUR3.0%22.20 EUR17.61 EUR-1.219.2845.2KOff
29 May 202621.75 EUR-1.7%22.11 EUR17.56 EUR-1.255.05158.3KOff
22 May 202622.13 EUR3.8%22.05 EUR17.51 EUR-1.108.17196.3KOff
15 May 202621.33 EUR0.9%21.92 EUR17.46 EUR-1.028.83459.1KOff
8 May 202621.14 EUR-4.6%21.82 EUR17.42 EUR-0.856.68261.6KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context